Diabetes Metab J.  2011 Aug;35(4):340-347. 10.4093/dmj.2011.35.4.340.

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor gamma Activity and on Glucose Uptake by Thiazolidinediones

• Lee KW
• Ku YH
• Kim M
• Ahn BY
• Chung SS
• Park KS

• KMID: 2281640
• DOI: http://doi.org/10.4093/dmj.2011.35.4.340

Abstract

BACKGROUND
Sulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic beta-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor gamma (PPARgamma), one of the nuclear receptors. In this study, we investigated the effects of sulfonylurea on PPARgamma transcriptional activity and on the glucose uptake via PPARgamma.
METHODS
Transcription reporter assays using Cos7 cells were performed to determine if specific sulfonylureas stimulate PPARgamma transactivation. Glimepiride, gliquidone, and glipizide (1 to 500 microM) were used as treatment, and rosiglitazone at 1 and 10 microM was used as a control. The effects of sulfonylurea and rosiglitazone treatments on the transcriptional activity of endogenous PPARgamma were observed. In addition, 3T3-L1 adipocytes were treated with rosiglitazone (10 microM), glimepiride (100 microM) or both to verify the effect of glimepiride on rosiglitazone-induced glucose uptake.
RESULTS
Sulfonylureas, including glimepiride, gliquidone and glipizide, increased PPARgamma transcriptional activity, gliquidone being the most potent PPARgamma agonist. However, no additive effects were observed in the presence of rosiglitazone. When rosiglitazone was co-treated with glimepiride, PPARgamma transcriptional activity and glucose uptake were reduced compared to those after treatment with rosiglitazone alone. This competitive effect of glimepiride was observed only at high concentrations that are not achieved with clinical doses.
CONCLUSION
Sulfonylureas like glimepiride, gliquidone and glipizide increased the transcriptional activity of PPARgamma. Also, glimepiride was able to reduce the effect of rosiglitazone on PPARgamma agonistic activity and glucose uptake. However, the competitive effect does not seem to occur at clinically feasible concentrations.

Keyword

Diabetes mellitus, type 2; Peroxisome proliferator-activated receptors; PPAR gamma; Sulfonylurea compounds; Thiazolidinediones

MeSH Terms

Adipocytes
Diabetes Mellitus, Type 2
Glipizide
Glucose
Insulin
Insulin Resistance
Peroxisome Proliferator-Activated Receptors
Peroxisomes
PPAR gamma
Receptors, Cytoplasmic and Nuclear
Sulfonylurea Compounds
Thiazolidinediones
Transcriptional Activation
Glipizide
Glucose
Insulin
PPAR gamma
Peroxisome Proliferator-Activated Receptors
Receptors, Cytoplasmic and Nuclear
Sulfonylurea Compounds
Thiazolidinediones